SuperworthBeta Bionics revenue BBNX
Sales by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- $119M
- Latest quarter, Q2 FY26
- $32M
- +38% on a year earlier
- Fiscal year 2025
- $100.3M
- +54% on the year before
Beta Bionics' revenue was $119M over the twelve months to Jun 30, 2026, up 53% on a year earlier.
In its latest quarter, Q2 FY26, it was $32M, up 38% on the same quarter a year before.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $100.3M | +54% |
| FY2024 | $65.1M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $32M | +38% | $119M | |
| Q1 FY26 | $27.6M | +57% | $110.2M | |
| Q4 FY25 | $32.1M | +57% | $100.3M | |
| Q3 FY25 | $27.3M | +63% | $88.6M | |
| Q2 FY25 | $23.2M | +54% | $78M | |
| Q1 FY25 | $17.6M | +36% | $69.8M | |
| Q4 FY24 | $20.4M | n/a | $65.1M | |
| Q3 FY24 | $16.7M | n/a | n/a | |
| Q2 FY24 | $15M | n/a | n/a | |
| Q1 FY24 | $12.9M | n/a | n/a |
Against its peers
Companies in Medical - Instruments & Supplies nearest Beta Bionics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| BBNXBeta Bionics | $119M | +53% a year |
| MOVMovado | $689.9M | +5% a year |
| IRMDIradimed | $86.3M | +11% a year |
| STAAStaar Surgical | $339.6M | +51% a year |
| BVSBioventus | $581.8M | +3% a year |
| CDRECadre | $685.6M | +20% a year |
| MDXGMimedx | $355.2M | −2% a year |
| TCMDTactile Systems Technology | $350.3M | +17% a year |
| EYENational Vision | $2B | +8% a year |
| LMATLemaitre Vascular | $262.4M | +12% a year |
| EMBCEmbecta | $1B | −8% a year |
| Peer median | $468.5M |
Where Beta Bionics ranks
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Beta Bionics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.